Drug maker Lupin Tuesday said it has appointed Alok Sonig as CEO US Generics and Global Head Generics R&D & Biosimilars.
Sonig will lead and have overall responsibility for the US Generics business, including R&D activities in India and the US, and the commercial side of the American business.
He will also be responsible for Lupin's global biosimilars business.
Most recently, Sonig was CEO of Developed Markets (US, Canada, Europe and Japan) at Dr Reddy's Laboratories. Prior to that Sonig spent nearly 15 years at Bristol-Myers Squibb, where he held several senior positions.
"His global experience, strategic perspective, and operational focus will help accelerate our team's efforts to strengthen and evolve our US generics business as we execute on near-term growth opportunities and navigate new platforms in complex generics and biosimilars," Lupin CEO Vinita Gupta said in a statement.
Sonig will be based out of Somerset, New Jersey and will report to Vinita Gupta and Nilesh Gupta Managing Director, Lupin.
Disclaimer: No Business Standard Journalist was involved in creation of this content
